Home> About Us>History
  • Year 2017

    Acquired the exclusive distribution rights in China for Alpha-Lipon (alpha-lipoid acid for injection) from German Stada Pharma.

    Acquired the national distribution rights in China of Mei Shi Yu (trazodone hydrochloride tablets) from Taiwan Lotus Pharma. 

    Acquired all rights of Calcium Carbonate D3 from GE Pharma, and initiated transferring the corresponding production protocols and process to Chongqing Hemony Pharma. 

    Acquired all rights of propylthiouracil tablets from German Herbrand.

    The company moved to Lhasa headquarters.  

    Completed the shareholder reform, Organization is restructured to a joint stock company, and the establishment of Hemony Pharmaceutical Co., Ltd. is completed.

  • Year 2016

    Acquired all rights of Besonin (budesonide nasal spray) from Taiwan Synmosa Biopharma.

    Acquired all rights of Hao ZhiBaclofen tablets) globally, as well as the commercial rights in China of Shi Rui DaSerrapeptase tablets) from Taiwan Weidar Chemical.

  • Year 2015

    Granted GMP certificate, and the new manufacturing base of Chongqing Hemony Pharma officially began production. 

    Guang Ya was divested from the portfolio so that we could better focus more on core business. 

  • Year 2014

    Acquired a well-known domestic CSO company, Beijing MDC, for and further increased national field force coverage for pharmaceutical products.

     In-licensed Cefobid (cefoperazone sodium for injection) manufactured by Pfizer for all commercial rights in China. 

  • Year 2013

    Set up the Hemony Pharma Holding platform.  

    In-licensed Factive (gemifloxacin nesylate tablets) from South Korean LGLS for all commercial rights in China.  

  • Year 2012

    Acquired Jun Zha to equip with manufacturing capability.   

    Chongqing Hemony Pharma (formerly Chongqing Huachang Pharma) was incorporated, and Jun Zha was relocated to Chongqing for the integrated R&D and production base. 

  • Year 2010

    Guang Ya was incorporated for expansion into drug distribution business in Chongqing.

  • Year 2005

    Partnered with India Ranbaxy to market generic Bacqure (Imipenem and Cilastatin Sodium for injection), which sets up another milestone for the company in commercializing imported drugs in China.

  • Year 2004

    Commissioned a number of domestic pharmaceutical companies for the development and production of selected generic drugs, such as:  cefoperazone sulbactam injection, aztreonam injection, ceftazidime injection.

    Also established the Medical Merchant Market Development team for national coverage. 

  • Year 2002

    Kai Yu was founded, as regional contracted sales agency in Chongqing area